Pfizer (PFE) is expected to report Q1 earnings before the market open on Tuesday, May 1 with a conference call scheduled for 10am ET.
Analysts are looking for EPS of 56c on revenue of $15.47B. The consensus range is 53c-59c for EPS and $15.22B-$15.81B for revenue, according to First Call. Positive catalysts for the drug giant may be seen coming from one of its newer drugs, Inlyta, as well as growth in Enbrel, Lyrica and Prevnar. Negative headwinds for Pfizer will be seen coming from generic erosion in Lipitor, as Q1 is its first full reporting period without market exclusivity in the former block buster drug. Investors will also be focused on details of the recent divestiture of its Nutritionals business to Nestle (NSRGY.PK) for $11.85B, which Leerink said should be viewed as a positive given the sale price. Investors may also get more details on Pfizer's plans for its Animal Health division, after the company's CEO recently said at its annual investor meeting that the company will divest the unit by way of a combination of an initial public offering and an exchange of shares with current stockholders.